We found the recent study by Maisano et al very thought-provoking, given the focus on the commercial experience using the Portico™ bioprosthetic valve (Abbott, Santa Clara, CA, USA) in the multicentre PORTICO-1 study1. We applaud the authors for conducting this important study which further adds to a growing body of evidence demonstrating the overall safety (low mortality) and acceptable clinical and haemodynamic outcomes (low transvalvular gradients and low rate of moderate-high paravalvular leak) of the Portico valve2,3,4.
While innovation in transcatheter aortic valve replacement (TAVR) devices and adoption of the procedure have occurred rapidly, it appears that ...
Sign in to read and download the full articleForgot your password?
Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com